MedTrace Logo

Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia

NCT03241888 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2024-09-26

No results posted yet for this study

Summary

To see if megestrol acetate plus Levonorgestrel-releasing intrauterine system (LNG-IUS) will not be inferior to returning the endometrial tissue to a normal state than megestrol acetate or LNG-IUS alone in patients with endometrial atypical hyperplasia.

Conditions

  • Atypical Endometrial Hyperplasia

Interventions

DRUG

Megestrol Acetate

At a dosage of 160 mg/day

DEVICE

Levonorgestrel-releasing Intrauterine System(LNG-IUS)

Active ingredient: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-04
Primary Completion
2020-06-18
Completion
2020-06-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03241888 on ClinicalTrials.gov